Anafranil is a branded medication whose active ingredient is clomipramine, a tricyclic antidepressant (TCA). It is supplied as an oral pill and is available in the strengths 10 mg, 25 mg, and 50 mg. In Hong Kong, Anafranil is classified as a prescription-only drug and is regulated by the Hong Kong Department of Health under the Pharmacy and Poisons Ordinance. The medication is used primarily to treat certain mood and anxiety disorders, and its therapeutic effects stem from the way it modifies neurotransmitter activity in the brain.
Clomipramine belongs to the tricyclic class of antidepressants. Its primary pharmacologic actions are:
By enhancing the signaling of these two neurotransmitters, clomipramine helps normalize mood and anxiety pathways that are often dysregulated in depressive and obsessive-compulsive disorders. The onset of noticeable clinical improvement typically begins within 2-4 weeks of consistent dosing, with maximal therapeutic effect reached after several weeks of treatment. The drug is well-absorbed after oral ingestion, undergoes extensive hepatic metabolism (primarily via CYP2D6), and has a half-life of roughly 30 hours, allowing once-daily or twice-daily dosing regimens.
Anafranil is approved by regulatory agencies for the following indications:
In Hong Kong, the Drug Office of the Department of Health aligns its approvals with the international labeling approved by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Physicians may also consider Anafranil for related anxiety conditions, but such use must be based on clinical judgment and patient response.
Research and clinical guidelines have explored additional uses for clomipramine beyond its approved indications. The following off-label applications have credible evidence, though they are not sanctioned by regulatory bodies for these purposes:
Off-label use requires medical supervision and an individualized risk-benefit assessment. Patients should discuss potential benefits and risks with their healthcare provider before initiating therapy for these conditions.
All dosage adjustments should be prescribed by a qualified healthcare professional who can evaluate efficacy and side-effect burden.
If a dose is missed, take it as soon as remembered unless it is close to the time of the next scheduled dose. In that case, skip the missed dose; do not double-dose.
Signs of overdose include severe drowsiness, cardiac arrhythmias, widened QRS complexes, and seizures. Immediate emergency care is required. Activated charcoal may be administered in the emergency setting, and sodium bicarbonate is the standard antidote for TCA-induced cardiac toxicity.
Abrupt cessation can lead to withdrawal symptoms such as irritability, insomnia, and flu-like sensations. Gradual tapering-usually reducing the dose by 10 mg every 1-2 weeks-is recommended to minimize discontinuation syndrome.
This article provides educational information about Anafranil and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Combining Anafranil with an SSRI can increase the risk of serotonin syndrome and may require dose adjustments. This combination should only be used under close medical supervision with careful monitoring for symptoms such as agitation, rapid heart rate, or fever.
Increase dietary fiber, fluid intake, and consider a mild stool softener after discussing options with your pharmacist. Persistent or painful constipation warrants prompt evaluation by a healthcare professional.
Yes, Anafranil tablets are a prescription medication and can be carried in original packaging with a copy of the prescription. Keep the medication in your hand luggage to avoid temperature extremes.
Commonly, Anafranil tablets are scored and bear imprint codes specific to the manufacturer, such as “CLM 10” for the 10 mg strength. Refer to the pill identifier on the packaging or consult a pharmacist for confirmation.
Moderate caffeine intake is generally acceptable, but excess caffeine may worsen anxiety or insomnia, especially during the early weeks of therapy. Monitor your own tolerance and adjust consumption accordingly.
Patients often report initial symptom relief after 2-4 weeks, with maximal benefit observed after 8-12 weeks of consistent dosing. Patience and adherence to the prescribed regimen are essential.
Clomipramine can occasionally cause changes in glucose metabolism, potentially leading to elevated blood sugar. Diabetic patients should monitor their levels closely and inform their physician of any significant shifts.
An initial ECG is recommended to assess baseline cardiac conduction. Subsequent ECGs may be needed if you develop cardiac symptoms, change doses significantly, or have underlying heart disease.
First-generation antihistamines (e.g., diphenhydramine) have anticholinergic properties that can intensify dry mouth and constipation. Second-generation antihistamines (e.g., loratadine) are generally safer but should still be discussed with your pharmacist.
Clomipramine is excreted in breast milk and may cause sedation or irritability in the infant. A thorough risk-benefit discussion with your obstetrician or pediatrician is essential before continuing the medication during lactation.
